ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. ThermoGenesis is transitioning to a CDMO model, launching 12 ReadyStart cGMP Suites projected to generate $10-$16 million annually. The company operates as a micro-cap public entity facing significant market capitalization challenges as of mid-2026.
Cyborg Score Rationale
ThermoGenesis faces severe headwinds with a near-zero stock price ($0.0001 as of May 2026) and minimal market capitalization ($1.75M as of June 2024). The company operates in a capital-intensive cell and gene therapy market with minimal quarterly revenues (~$9.6M trailing TTM) and is attempting a strategic pivot to a CDMO model. Limited visibility into growth acceleration despite targeted revenue projections from new platform launches.
Top Insights
Operating with nominal market capitalization and micro-cap trading dynamics, indicating severe investor skepticism or potential bankruptcy risk
Transitioning business model from equipment sales to contract development and manufacturing services (CDMO), a higher-margin, recurring-revenue opportunity
Positioned in high-growth cell and gene therapy markets, particularly CAR-T immunotherapy manufacturing, which remains nascent and capacity-constrained
Minimal recent public disclosure suggests limited investor communication or market engagement, raising transparency concerns
Named Competitors
Cell Processing Services — Contract development and manufacturing for cell-based therapies
Automated Cell Banking Systems — Cell and gene therapy CDMO and biotech services
CAR-T Manufacturing Automation — Cell therapy manufacturing and lentiviral vector production
Recent Developments
(May 2026) Stock price trading near zero ($0.0001), reflecting extreme market stress